A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT06877247 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: [14C] SHR6508 Injection

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.